Research programme: NRF1 gene transcriptional regulators - Infixion Bioscience
Latest Information Update: 04 Oct 2022
At a glance
- Originator iNFixion Bioscience
- Class Antineoplastics
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neurofibromatosis 1
Most Recent Events
- 29 Sep 2022 Research programme: NRF1 gene transcriptional regulators - Infixion Bioscience is available for licensing as of 29 Sep 2022. https://www.infixionbio.com/
- 20 Sep 2022 iNFixion Bioscience receives third SBIR grant from National Institute of Neurological Disorders and Stroke (NINDS) for development in Neurofibromatosis (NF1)
- 20 Sep 2022 Early research in Neurofibromatoses 1 in USA (unspecified route)